Veeda Group has rebranded to Veeda Lifesciences, reflecting its evolution into a drug development enterprise. It comprises four strategic units: Clinical Trials, Healthy Volunteer Services, Biopharma ...
Patients would pay no more than $25 for certain name-brand medications to treat chronic illnesses, including insulin for diabetes, and face no costs whatsoever for similar generic options under a ...
Medicare beneficiaries will see a significant reduction in out-of-pocket costs for prescription drugs in 2025. The $2,000 cap will provide substantial savings for millions of enrollees.
"Uncontrolled cravings are a significant barrier to weight loss that often goes unaddressed in obesity management conversations," said Dr. Angela Golden, DNP. "The 'Cravings Don't Own Me' campaign ...
As on 30-09-2024, the company has a total of 55.37 Crore shares outstanding.Generic Pharmasec Share Price Today is Rs. 2.96 as on 30 Dec, 2024, 12:38 PM IST. On previous day, the Generic Pharmasec ...